Havana, Cuba

Yasser Perera Negrín

This inventor holds 1 USPTO granted patent and 2 published patent applications and 2 EPO patents. Top assignees: Biorec S.a., Centro De Ingenieria Genetica Y Biotecnologia. Active years: 2016.

USPTO Granted Patents = 1 

% Patents Active = 100.0


Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yasser Perera Negrín: Innovator in Cancer Treatment

Introduction

Yasser Perera Negrín is a notable inventor based in Havana, Cuba. He has made significant contributions to the field of cancer treatment through his innovative pharmaceutical inventions. His work focuses on improving the efficacy and reducing the toxicity of anticancer therapies.

Latest Patents

Yasser Perera Negrín holds a patent for a pharmaceutical combination aimed at the treatment and/or chemosensibilization of refractory tumors to anticancer drugs. This invention involves a combination of a Casein kinase 2 (CK2) peptide inhibitor, known as P15, along with standard chemotherapeutic drugs. The combination allows for a more efficient concentration of each drug, achieving a dosage that is 10- to 100-fold lower than when used alone. This innovative approach not only enhances the effectiveness of the treatment but also reduces toxicity, making it a crucial advancement in cancer therapy.

Career Highlights

Throughout his career, Yasser has worked with prominent organizations such as Biorec S.A. and the Center for Genetic Engineering and Biotechnology. His experience in these institutions has contributed to his expertise in pharmaceutical development and cancer research.

Collaborations

Yasser has collaborated with notable colleagues, including Daniel Eduardo Gomez and Daniel Fernando Alonso. These partnerships have further enriched his research and development efforts in the field of oncology.

Conclusion

Yasser Perera Negrín's innovative work in cancer treatment exemplifies the potential of pharmaceutical advancements to improve patient outcomes. His contributions are paving the way for more effective and less toxic cancer therapies.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…